Clinical utility of tumour markers in skeletal metastasis of unknown primary at the initial visit [0.03%]
初次就诊时不明原发灶骨骼转移肿瘤标志物的临床应用价值
Kensaku Yamaga,Keiichi Akahori,Mari Osaki et al.
Kensaku Yamaga et al.
Background: Skeletal metastasis of unknown primary at the initial visit represents a clinically important subset of metastatic bone tumours, accounting for ~7.8%-21.7% of all skeletal metastases. This condition differs fr...
Adverse impact of bladder biopsy on the rate of intravesical recurrences following radical nephroureterectomy for upper tract urothelial carcinoma [0.03%]
根治性肾输尿管全长切除术中膀胱活检对上尿路尿路上皮癌患者膀胱复发率的不利影响
Tomonori Kanagawa,Ichiro Yonese,Takehiro Nakamura et al.
Tomonori Kanagawa et al.
Introduction: Seeding and implantation are major mechanisms of intravesical recurrence (IVR) following the radical nephroureterectomy (RNU) of upper tract urothelial carcinoma (UTUC). We herein hypothesized that bladder b...
POU2F3 expression in lung squamous cell carcinoma: transcriptomic and immunohistochemical profiling with prognosis [0.03%]
肺鳞状细胞癌中POU2F3的表达:转录组和免疫组织化学特征及预后分析
Suguru Mitsui,Naoe Jimbo,Hiroyuki Ogawa et al.
Suguru Mitsui et al.
Background: Lung squamous cell carcinoma (LUSC) lacks well-defined molecular targets. This study investigated the clinical and biological relevance of POU class 2 homeobox 3 (POU2F3), a tuft cell-associated transcription ...
Age-standardized mortality-to-incidence ratio for larynx cancer in the world [0.03%]
全球喉癌年龄标准化死亡与发病率比值
Sumiyo Okawa,Hadrien Charvat
Sumiyo Okawa
Correction to: Reclassification of a BRCA2 variant, c.8487G > A (p.Gln2829Gln) located at 3' end of exon 19, from uncertain significance to likely pathogenic based on splicing alteration: a case report [0.03%]
对BRCA2变异c.8487G>A(p.Gln2829Gln):基于剪接改变的外显子19′端重新分类从意义未明到很可能致病:病例报告
Published Erratum
Japanese journal of clinical oncology. 2026 May 4:hyag082. DOI:10.1093/jjco/hyag082 2026
Optimizing management of small renal masses: a patient-centered approach to minimize overtreatment [0.03%]
针对小肾肿物的优化管理:最小化过度治疗的患者中心方法
Goshi Kitano,Takahiro Kojima,Takahiro Osawa et al.
Goshi Kitano et al.
Small renal masses (SRMs) usually have a favorable prognosis. Many studies have shown that cancer-specific survival (CSS) is comparable among various treatment options, such as partial nephrectomy, percutaneous thermal ablation, stereotacti...
Impact of treatment volume on outcomes for patients with penile cancer at relatively low-volume centers in Japan [0.03%]
日本低量中心阴茎癌患者的治疗量对预后的影响分析
Yoji Murakami,Takahiro Yamaguchi,Masato Goya et al.
Yoji Murakami et al.
Objectives: To investigate whether there are differences in treatment approaches, including complications according to the volume of treatment experience for penile cancer, and whether such differences affect patient prog...
Adipose tissue and survival among patients with advanced biliary tract cancer [0.03%]
胆道癌晚期患者的脂肪组织与生存率之间的关系
Shinya Takaoka,Tsuyoshi Hamada,Naminatsu Takahara et al.
Shinya Takaoka et al.
Background: Adiposity may promote the progression of different types of cancer. The prognostic significance of visceral and subcutaneous adipose tissue has not been thoroughly investigated in patients with advanced biliar...
Bayesian reanalysis of the NIAGARA trial using reconstructed individual patient data: perioperative durvalumab in cisplatin-eligible muscle-invasive bladder cancer [0.03%]
尼加拉试验的贝叶斯再分析(采用重建的患者个体数据):度伐利尤单抗用于顺铂适用的肌层浸润性膀胱癌的新辅助或辅助治疗
Kohei Hirose,Soichiro Yoshida,Wei Chen et al.
Kohei Hirose et al.
Objectives: To provide decision-focused estimates of the benefit of perioperative durvalumab in cisplatin-eligible muscle-invasive bladder cancer using Bayesian modeling of reconstructed individual patient data (rIPD) fro...
Long-term outcomes of high-dose-rate brachytherapy combined with moderately hypofractionated external beam radiotherapy for high-risk localized prostate cancer [0.03%]
高剂量率腔内放射治疗与中等低分割外照射治疗对高危局限性前列腺癌长期疗效的比较研究
Kenta Ohmatsu,Yaichiro Hashimoto,Mirei Kamori et al.
Kenta Ohmatsu et al.
Background: High-dose-rate brachytherapy (HDR-BT) combined with external beam radiotherapy (EBRT) is an established dose-escalation strategy for high-risk localized prostate cancer; however, long-term outcomes using a str...